Dr. Aileen Marty, Infectious Disease Specialist and Professor at Florida International University, joins Bob Sirott to talk ...

On Monday, Novavax Inc (NVAX) stock saw a decline, ending the day at $10.14 which represents a decrease of $-0.04 or -0.39% from the prior close of $10.18. The stock opened at $10.1 and touched a low ...

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Vaccine maker Novavax (NASDAQ: NVAX) has had a rollercoaster of a year. In May, the company's shares soared after it ...

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. (“Novavax” or ...

Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

Shares of US protein-based vaccine maker Novavax closed down 19.4% at $10.15 yesterday having dropped as much as 24%, on the ...

In the latest market close, Novavax (NVAX) reached $10.35, with a +1.97% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.02%. On the other ...

Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.

Shares of American pharmaceutical company Novavax (NVAX) fell 19% on reports that the U.S. Food and Drug Administration (FDA) ...

NVAX's COVID-19-flu combination and stand-alone flu vaccines have been placed on hold after a study participant who took the ...